Xeris added a director with pharmaceutical and finance experience, and the filing grants him an initial award worth about $450,000 plus future annual awards near $300,000. The filing reports no change to Xeris's products, sales, or profit, so the appointment does not clearly change the company's outlook.
His experience in pharmaceutical leadership and finance could help with board and audit oversight. The filing also reports an initial award worth about $450,000 and eligibility for annual awards worth about $300,000.
Follow Xeris Biopharma Holdings, Inc. (XERS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for XERS